DE602004029767D1 - Detektion, überwachung und behandlung von krebs - Google Patents

Detektion, überwachung und behandlung von krebs

Info

Publication number
DE602004029767D1
DE602004029767D1 DE602004029767T DE602004029767T DE602004029767D1 DE 602004029767 D1 DE602004029767 D1 DE 602004029767D1 DE 602004029767 T DE602004029767 T DE 602004029767T DE 602004029767 T DE602004029767 T DE 602004029767T DE 602004029767 D1 DE602004029767 D1 DE 602004029767D1
Authority
DE
Germany
Prior art keywords
detection
treatment
cancer
monitoring
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004029767T
Other languages
English (en)
Inventor
James Ironside Bruce
Sotiris Missailidis
Katalin Eszter Borbas
Catia Sofia Ferreira
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Open University
Original Assignee
Open University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Open University filed Critical Open University
Publication of DE602004029767D1 publication Critical patent/DE602004029767D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004029767T 2003-03-10 2004-03-10 Detektion, überwachung und behandlung von krebs Expired - Lifetime DE602004029767D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0305422.8A GB0305422D0 (en) 2003-03-10 2003-03-10 Detection, monitoring and treatment of cancer
PCT/GB2004/001028 WO2004081574A2 (en) 2003-03-10 2004-03-10 Detection, monitoring and treatment of cancer

Publications (1)

Publication Number Publication Date
DE602004029767D1 true DE602004029767D1 (de) 2010-12-09

Family

ID=9954463

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004029767T Expired - Lifetime DE602004029767D1 (de) 2003-03-10 2004-03-10 Detektion, überwachung und behandlung von krebs

Country Status (7)

Country Link
US (1) US20070160526A1 (de)
EP (4) EP1601970B1 (de)
AT (1) ATE486284T1 (de)
CA (1) CA2518783A1 (de)
DE (1) DE602004029767D1 (de)
GB (1) GB0305422D0 (de)
WO (1) WO2004081574A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007023766A1 (ja) * 2005-08-23 2007-03-01 National University Corporation Gunma University 含ケイ素置換基を導入した一重項酸素発生剤
GB2437727B (en) * 2006-05-04 2011-04-20 Univ Open Aptamers directed to MUC1
WO2007128109A1 (en) * 2006-05-04 2007-11-15 University Health Network Aptamers that recognize the carbohydrate n-acetylgalactosamine (galnac)
AU2010234459A1 (en) * 2009-04-08 2011-11-03 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics
WO2010140834A2 (ko) * 2009-06-01 2010-12-09 성균관대학교산학협력단 췌장암 세포 또는 조직에 특이적으로 결합할 수 있는 핵산 압타머 및 그 용도
CN103160513B (zh) * 2011-12-16 2015-07-01 中国医学科学院基础医学研究所 Muc1蛋白核酸适配子、复合体、组合物及其用途
EP2639227A1 (de) * 2012-03-14 2013-09-18 Bracco Imaging S.p.A Neue Klasse von Diazepinderivatchelatbildnern und Komplexe mit paramagnetischen Metallen als MRI-Kontrastmittel
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
CA2938776C (en) 2014-02-05 2023-08-22 Deakin University Aptamer construct
CN105879027B (zh) * 2014-05-16 2020-03-27 中国科学院苏州纳米技术与纳米仿生研究所 核酸配体修饰的金纳米-石墨烯复合材料及其制备方法和应用
US10081776B2 (en) 2015-05-11 2018-09-25 Northwestern University Cyclen friction modifiers for boundary lubrication
EP3969591A1 (de) * 2019-05-15 2022-03-23 Squadra Lifesciences, Inc Aptamere gegen glioblastom

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915958A (en) 1972-05-22 1975-10-28 Icn Pharmaceuticals 6-Substituted purine nucleotides
US3960840A (en) 1972-12-29 1976-06-01 University Of Illinois Foundaton Fluorescent derivatives of adenine-containing compounds
US4038480A (en) 1973-09-17 1977-07-26 Icn Pharmaceuticals, Inc. 6-aminocarbonyl purine 3',5'-cyclic nucleotides
GB1529974A (en) 1974-10-15 1978-10-25 Asahi Chemical Ind Nucleotide derivatives and process for preparing the same
US3968101A (en) 1974-12-20 1976-07-06 Icn Pharmaceuticals, Inc. 8-Substituted cyclic nucleotides by free radical alkylation and acylation
US4048307A (en) 1974-12-26 1977-09-13 Asahi Kasei Kogyo Kabushiki Kaisha Cyclic adenosine monophosphate 8-substituted derivatives
US4267171A (en) 1979-07-02 1981-05-12 The Regents Of The University Of California C-5 Substituted cytosine nucleosides
US6280932B1 (en) * 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6699843B2 (en) * 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6268350B1 (en) * 1997-10-23 2001-07-31 Biocrystal Ltd. Polynucleotides for inhibiting metastasis and tumor cell growth
US6418338B1 (en) * 1998-02-06 2002-07-09 Phylatron Ltd. Method for detecting and surgically removing lymphoid tissue involved in tumor progression
US6224866B1 (en) * 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
ES2288040T3 (es) 1998-12-18 2007-12-16 Bristol-Myers Squibb Pharma Company Medicamentos antagonistas del receptor de la vitronectina.
US6251616B1 (en) * 1999-01-14 2001-06-26 Biocrystal Ltd. Methods and assay kits for detecting altered mononuclear cell phenotype related to a pro-tumor immune response
WO2001052899A1 (en) * 2000-01-21 2001-07-26 Mallinckrodt Inc. Chelating agents and method for their use as tandem metal chelators and hydrophilic spacers for medical diagnosis and therapy
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
US6376190B1 (en) * 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
JP2004526671A (ja) 2000-10-31 2004-09-02 ブラッコ インターナショナル ベースローテン フェンノートシャップ 診断および治療への適用において使用するための抗酸化剤の金属キレート配位子との結合体
EP1381392A4 (de) * 2001-04-24 2005-03-23 Ts Corp Synthetischer katalysator für die selektive spaltung von protein und verfahren für die selektive spaltung von protein unter verwendung dieses katalysators
WO2003106659A2 (en) * 2002-06-18 2003-12-24 Archemix Corp. Aptamer-toxin molecules and methods for using same

Also Published As

Publication number Publication date
EP2209000A3 (de) 2010-10-27
EP2209000A2 (de) 2010-07-21
EP1601970B1 (de) 2010-10-27
EP2287613A2 (de) 2011-02-23
WO2004081574A2 (en) 2004-09-23
GB0305422D0 (en) 2003-04-16
EP1601970A2 (de) 2005-12-07
EP1806585A1 (de) 2007-07-11
WO2004081574A3 (en) 2004-12-16
CA2518783A1 (en) 2004-09-23
US20070160526A1 (en) 2007-07-12
ATE486284T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE602004026891D1 (de) Tlr7-liganden zur behandlung von hepatitis c
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
ATE486284T1 (de) Detektion, überwachung und behandlung von krebs
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
WO2003087831A3 (en) Proteins involved in breast cancer
ATE448232T1 (de) Substituierte heterozyklen
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
NO994932L (no) Blandinger og fremgangsmåter for behandling og diagnose av brystkreft
CY1111256T1 (el) Παραγωγα αζαδικυκλοοκταν-3-ονης και χρηση τους
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602004003952D1 (de) Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
CY1114757T1 (el) Παραγωγα οξαζινης και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602005019341D1 (de) System zur Behandlung von Sterilisationskassetten mit visuellem Dual-Kode Leser
ATE424823T1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
ATE406895T1 (de) 4-phenyl-5-oxo-l,4,5,6,7,8-hexahydrochinolin- derivate als arzneimittel zur behandlung von unfruchtbarkeit
DE602005015434D1 (de) Mittel zur behandlung von psychoneurotischen krankheiten
ITBO20030050A1 (it) Macchina per il trattamento di prodotti farmaceutici.
DE502005002104D1 (de) Hesperidin zur Behandlung von Epilepsie